Nanostring Tech (NASDAQ: NSTG) reported Q2 EPS of ($0.58), $0.07 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $10.2 million.

The company also announced that it has received market approval from the Australian Therapeutic Goods Administration (TGA), clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s risk of distant recurrence of disease. The Prosigna Assay was launched in the U.S. in December 2013 and is also CE Marked for in vitro diagnostic use in the European Union and Israel, and is licensed for use in Canada.

For earnings history and earnings-related data on Nanostring Tech (NSTG) click here.